This study is testing two different treatment approaches for people with mesothelioma that can potentially be removed by surgery. One group will receive a combination of chemotherapy (cisplatin or carboplatin and pemetrexed) along with two immunotherapy drugs, durvalumab and tremelimumab. The other group will receive only the immunotherapy drugs, durvalumab and tremelimumab. The main goal is to see if either of these treatments can improve how long patients live without their cancer returning after surgery, aiming for more than 60% of patients to be recurrence-free at one year. The study plans to enroll 52 participants and is currently unclear on its recruitment status. You may be eligible if you are 18 or older and have mesothelioma that a surgeon believes can be removed.

Study design

This is a randomized Phase Ib/IIa study with two groups, enrolling a total of 52 participants. It compares two different treatment combinations.

What's involved

Participants will receive treatment for 3 cycles before surgery, and then continue with durvalumab for up to 12 months after surgery. Tremelimumab will be given up to cycle 5.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint measures recurrence-free survival at one year after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.